RANOPTO

Google image searchProduct monograph

Active ingredient

ranibizumab, 10 MG/ML

DIN: 02542250

Dosage form(s): SOLUTION

Route(s) of administration: INTRAVITREAL

Description: SINGLE USE VIAL

Schedule: Prescription / Schedule D

Company: TEVA CANADA LIMITED

Date: 26-FEB-2024

ATC:

• S01 — OPHTHALMOLOGICALS (ATC, ATC/DDD, )
• S01L — OCULAR VASCULAR DISORDER AGENTS (ATC, ATC/DDD)
• S01LA — Antineovascularisation agents (ATC, ATC/DDD)
• S01LA04 — RANIBIZUMAB (ATC/DDD)

Reference brand drug: Lucentis

External Links for Ranopto

Search on Google

• Ranopto side effects
• Ranopto dosage
• ranibizumab side effects
• ranibizumab dosage

Teva Canada Limited

Go to Teva website to see drug product details. Sometimes you can find ranopto photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.